Skip to main content
Premium Trial:

Request an Annual Quote

Inpharmatica and Galapagos Genomics Sign Drug Discovery Collaboration

NEW YORK, April 29 - Inpharmatica and Galapagos Genomics have agreed to collaborate on a drug discovery project using Inpharmatica's chemogenomics technology and Galapagos' adenoviral expression platform, the companies said today.


Under the agreement, Galapagos, of Mechelen, Belgiumwill provide Inpharmatica with targets for internal disease programs, which Inpharmatica, of London, will evaluate using PharmaCarta, its chemogenomics technology. Galapagos will also provide Inpharmatica acces to its PhenoSelect adenoviral expression platform for validation in-house some of the nuclear receptors that Inpharmatica has discovered.


The companies did not disclose the financial terms of the agreement.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.